Abstract
Twenty-one schizophrenic subjects, who had been neuroleptic-free, were tested for responsiveness to dopaminergic agonists: Apomorphine emesis threshold was determined and change in psychopathology after 0.5 mg/kg d-amphetamine orally was rated. The subjects' subsequent response to neuroleptic treatment were also determined. Sensitivity to apomorphine emesis was also determined in a nonschizophrenic control group. Apomorphine emesis threshold was not significantly different in the schizophrenic and control groups. Correlations were done between baseline psychopathology, apomorphine sensitivity, and changes in psychopathology after amphetamine and after neuroleptic treatment. On the Brief Psychiatric Rating Scale (BPRS), baseline psychopathology correlated with improvement after neuroleptics and, on the clinical global impressions (CGI), increase of psychopathology after amphetamine also correlated with improvement after neuroleptic treatment. An inverse correlation was found between several indices of sensitivity to amphetamine (psychopathology change) and emetic sensitivity to apomorphine. An examination of individual subjects' responses to amphetamine and, subsequently, neuroleptics, suggested that in the absence of significant clinical change after amphetamine a brisk therapeutic response to neuroleptics was rare:
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Angrist, B., Lee, H. K., Gershon, S.: The antagonism of amphetamine-induced symptomatology by a neuroleptic. Am. J. Psychiatry 131, 817–819 (1974)
Borison, H. L., Brizzee, K. R.: Morphology of the emetic chemoreceptor trigger zone in cat medulla oblongata. Proc. Soc. Exp. Biol. Med. 77, 38–42 (1951)
Bowers, M. B.: Central dopamine turnover in schizophrenic syndromes. Arch. Gen. Psychiatry 31, 138–146 (1974)
Carlsson, A.: Antipsychotic drugs, neurotransmitters, and schizophrenia. Am. J. Psychiatry 135, 164–173 (1978)
Carlsson, A., Lindqvist, M.: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta. Pharmacol. Toxicol. (Kbh.) 20, 140–144 (1963)
Clement-Cormier, Y. C., Kebabian, J. W., Petzold, G. L.: Dopamine-sensitive adenylate cyclase in mammalian brain: A possible site of action of antipsychotic drugs. Proc. Natl. Acad. Sci. USA 71, 1113–1117 (1974)
Cools, A., Van Rossum, J. M.: Excitation-mediating and inhibition-mediating dopamine receptors: A new concept toward a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data. Psychopharmacologia 45, 243–254 (1976)
Creese, I., Burt, D. R., Snyder, S. H.: Dopamine receptor binding. Differentiation of agonist and antagonist states with H3 dopamine and H3 haloperidol. Life Sci 17, 993–1002 (1975)
Creese, I., Burt, D. R., Snyder, S. H.: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481–483 (1976)
Garau, L., Govoni, S., Stefanini, E., Trabucchi, M., Spano, P. F.: Dopamine receptors: Pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum. Life Sci. 280, 1745–1750 (1978)
Guy, W.: ECDEU Assessment manual for psychopathology. Washington, D.C.: U.S. Department of Health, Education and Welfare (1976)
Hyttel, J.: Effects of neuroleptics on H3 haloperidol and H3 cis (Z) flupenthixol binding and on adenylate cyclase in vitro. Life Sci. 23, 551–556 (1978)
Iversen, L. L.: Dopamine receptors in the brain: A dopamine-sensitive adenylate cyclase models synaptic receptors, illuminating antipsychotic drug action. Science 188, 1084–1089 (1975)
Janowsky, D. S., El-Yousef, K., Davis, J. M., Sekerke, H. J.: Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch. Gen. Psychiatry 28, 185–191 (1973)
Janowsky, D. S., Davis, J. M.: Dopamine, psychomotor stimulants and schizophrenia: Effects of methylphenidate and the stereoisomers of amphetamine in schizophrenics. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, E. Usdin, ed., pp. 75–101. New York: Raven 1974
Jaussen, P. A. J., Niemegcers, C. S. E., Schellekens, K. H. L.: Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data. In: Neuroleptic activity spectra for rats. Arzneim. Forsch. 15, 104–110 (1965)
Johnstone, E. C., Frith, C. D., Crow, T. J., Carney, M. W. P., Price, J. S.: Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet I, 848–851 (1978)
Kebabian, J. W.: Multiple classes of dopamine receptors in mammalian central nervous system: The involvement of dopamine sensitive adenyl cyclase. Life Sci. 23, 479–483 (1978)
Langer, G., Sachar, E. J., Gruen, P. H., Halpern, F. S.: Human prolactin responses to neuroleptic drugs correlate with antipsychotic potency. Nature 260, 639–640 (1977)
Langer, G., Sacher, E. J., Halpern, F. S.: The prolactin response to neuroleptic drugs, a rest of dopamine blockade: Neuroendocrine studies in normal men. J. Clin. Endocrinol. Metab. 45, 996–1002 (1977)
Matthysse, S.: Antipsychotic drug actions: A clue to pathology of schizophrenia? Fed. Proc. 32, 200–205 (1973)
Meltzer, H. Y., Sachar, E. J., Frantz, A. G.: Serum prolactin in newly admitted psychiatric patients. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, E. Usdin, ed., pp. 229–315. New York: Raven 1974
Post, R. M., Fink, E., Carpenter, W. T., Goodwin, F.: Cerebrospinal amine metabolites in acute schizophrenia. Arch. Gen. Psychiatry 32, 1063–1069 (1975)
van Praag, H. M., Korf, J., Lakke, J. P. W. F., Schut, T.: Dopamine metabolism in depressions, psychoses, and Parkinson's disease: The problem of specificity of biologic variables in behavior disorders. Psychol. Med. 5, 138–146 (1975)
Seeman, P., Tedesco, J. L., Lee, T., Chou-Wong, M., Muller, P., Bowels, J., Whitaker, P. M., McManus, C., Tittler, M., Weinreich, P., Friend, W. C., Brown, G. M.: Dopamine receptors in the central nervous system. Fed. Proc. 37, 130–136 (1978)
Snyder, S. H., Banerjee, S. P., Yamamura, H. I., Greenberg, D.: Drugs, neurotransmitters and schizophrenia. Science 184, 1243–1253 (1974)
Spitzer, R. L., Endicot, J., Robins, E.: Research diagnostic criteria: Rationale and reliability. Arch. Gen. Psychiatry 35, 733–782 (1978)
Stevens, J. R.: An anatomy of schizophrenia? Arch. Gen. Psychiatry 29, 177–189 (1973)
Thierrey, A. M., Blanc, G., Sobel, A., Stinus, L., Glowinski, J.: Dopaminergic terminals in the rat cortex. Science 182, 499–501 (1973)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Angrist, B., Rotrosen, J. & Gershon, S. Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology 67, 31–38 (1980). https://doi.org/10.1007/BF00427592
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00427592